Table 2.
Echocardiographic and doppler parameters
| Groups | Control | DM | DM-MSC | DM-Anak |
|---|---|---|---|---|
| LVEDD (cm) end study | 0.55 ± 0.007 | 0.80 ± 0.04acd | 0.69 ± 0.04abd | 0.62 ± 0.006abc |
| EF % end study | 87.28% ± 2.19 | 73.42% ± 2.4acd | 81.43% ± 3.8ab | 82.42% ± 2.63b |
| FS% end study | 52.25% ± 3.86 | 39.91% ± 1.6acd | 48.62% ± 5.28bd | 56.67% ± 1.53bc |
| E wave(cm/s) end study | 65.97 ± 5.19 | 59.50 ± 11.53cd | 77.56 ± 4.83b | 75 ± 3.24b |
| A wave (cm/s) end study | 32.34 ± 4.7 | 53.19 ± 5.12ad | 58.27 ± 13.28ad | 30.16 ± 3.36bc |
| E/A end study | 2.06 ± 0.25 | 1.17 ± 0.29ad | 1.38 ± 0.30ad | 2.5 ± 0.31bc |
| DT (ms) end study | 46.80 ± 2.39 | 62.20 ± 2.49acd | 46.20 ± 5.31b | 40.33 ± 4.04b |
Results of study were for eight observations compared as mean ± SD. Significance was if p < 0.05. a: Statistically significant compared to the control group. b: Statistically significant compared to the diabetic untreated group (p < 0.05). c: Statistically significant compared to the diabetic group treated with stem cell therapy (BM-MSCs). d: Statistically significant compared to the diabetic group treated with anakinra (Anak)